Searched for
GILEAD LIFE SCIENCES
Saptagir Laboratories signs deal with Jubilant Generics to manufacture 'Remdesivir'Remdesivir is an experimental antiviral drug developed by Gilead Sciences, Inc. as a course of treatment for Covid-19. Gilead entered into ...
Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vialThe DCGI has approved the company's remdesivir 100 mg per vial for restricted emergency use in India as part of the regulator's accelerated...
Gilead won't launch its Covid drug in JulyGilead has issued licences to nine generic drug companies to make and sell remdesivir. Six of the companies are Indian - Hetero, Cipla, Dr ...
Cipla launches generic remdesivir for coronavirus patientsThe USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of coron...
FDA warns against co-administration of remdesivir with CQ or HCQ for COVID-19 patients"FDA is warning health care providers that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not r...
Awaiting critical Remdesivir safety data from companies: DCGIApart from BDR, all have entered into voluntary licensing agreements with Gilead Science, US-based patent holder of this drug. Gilead said ...
Dr Reddy’s inks licensing pact with Gilead for Remdesivir to treat Covid-19The Hyderabad headquartered drug maker will obtain technology transfer from Gilead for manufacturing of the drug wherein the Indian firm wo...
Raghava Life Sciences in talks with formulators for potential Covid drug FavipiravirFavipiravir, a generic version of Avigan that is used to treat influenza in Japan, is being studied as an experimental drug in treating the...
Indian licensees free to price Remdesivir: GileadUS drug maker to launch own brand of Covid-19 experimental drug in the country next month. Gilead has licensed the drug to four companies —...
India's drug regulator grants Gilead Sciences marketing authorisation for remdesivirThe approval process for remdesivir was accelerated in view of the emergency situation and the unmet need for medicines in light of the cor...
BDR in pact to make Gilead drug for CiplaIn late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangemen...
Jubilant Life Sciences Q4 results: Posts Rs 260.49 crore profitThe company had posted a net loss of Rs 100.65 crore for the corresponding period of the previous fiscal.
BDR Pharmaceuticals move on Remdesivir clone irks GileadThe Indian company had submitted its application for manufacturing the Covid-19 drug to the Drug Controller General of India (DCGI) last we...
Covid-19 treatment: Cipla, Hetero Lab get nod to manufacture and sell RemdesivirCipla, Hetero, and Jubilant Lifesciences have signed voluntary licensing agreements with Gilead.
Cipla and Hetero seek clinical trial waiver for RemdesivirWhile all new drugs must undergo trials before getting marketing approval in India, the regulator can grant exemptions in public interest a...
More companies in talks for Remdesivir licenceThis week, Cipla, Jubilant Life Sciences, Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received ...
Gilead sign licensing deal for Remdesivir with three Indian companiesET had reported on May 5 that Gilead Sciences was in talks with several Indian companies including Jubilant Life Sciences for a licensing d...
India may soon get treatment for Hepatitis CThe drug called Epclusa which is developed to treat all genotypes of the Hepatitis C virus by Gilead Sciences in its latest breakthrough tr...
US group seeks to block Gilead drug patent in India"India's patent law doesn't give monopolies for old science or for compounds already in the public domain," Tahir Amin, director of I-MAK s...
- Aids drug prices to fall if Gilead fails to defend patent application
Price of a crucial AIDS drug may fall further if Cipla and AIDS patients succeed in their challenge to a patent application filed here by U...